Pulmozyme Efficacy & Tolerability: Lung Function

Help patients improve lung function with Pulmozyme

Pulmozyme provided sustained lung function improvement in patients with FVC>40% predicted1

 

 

Young patients with early disease also benefitted from Pulmozyme in a 2-year clinical trial.

Pulmozyme maintained or improved lung function in patients with FVC ≥85% predicted, aged 6 to 10 years

FEF = forced expiratory flow between 25% and 75% of vital capacity

1. Pulmozyme SmPC, Electronic Medicines Compendium, accessed 10/8/18

25. Fuchs HJ et al. Effect of aerosolized recombinant humsn Dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-642.

26. Quan JM et al. A two-year randomized. Placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001;139(6):813-820.